Is Opdivo Chemotherapy?
No, Opdivo (nivolumab) is not chemotherapy—it is an immunotherapy agent, specifically a fully humanized IgG4 monoclonal antibody that blocks the PD-1 immune checkpoint.
Mechanism of Action
Opdivo works through an entirely different mechanism than traditional chemotherapy:
- Nivolumab inhibits the interaction between programmed cell death protein 1 (PD-1) on activated lymphocytes and its ligands (PD-L1/PD-L2), thereby enhancing the immune system's ability to recognize and attack tumor cells 1, 2
- Chemotherapy directly kills rapidly dividing cells through cytotoxic mechanisms (e.g., DNA damage, mitotic inhibition)
Clinical Evidence Distinguishing the Two
The distinction is clearly demonstrated in clinical trials where nivolumab is directly compared against chemotherapy as separate treatment options:
- In CheckMate 017 and CheckMate 057 trials, nivolumab was tested versus docetaxel (a chemotherapy agent) in previously-treated NSCLC, showing superior overall survival 1
- In CheckMate 648, nivolumab was tested versus cisplatin and fluorouracil (chemotherapy agents) in esophageal cancer 2
- The FDA label explicitly describes nivolumab as an alternative to chemotherapy in multiple indications 2
Toxicity Profile Differences
The adverse event profiles further distinguish these drug classes:
- Nivolumab: Grade ≥3 treatment-related adverse events occurred in ≤10% of patients, with immune-related adverse events (hypothyroidism, pneumonitis, colitis) being characteristic 1
- Chemotherapy (docetaxel): Grade ≥3 adverse events occurred in ~55% of patients, with typical chemotherapy toxicities like myelosuppression 1
Important Clinical Caveat
While nivolumab is not chemotherapy, it is frequently combined with chemotherapy in certain treatment regimens:
- CheckMate 648 evaluated nivolumab plus cisplatin and fluorouracil for esophageal cancer 2
- CheckMate 816 studied nivolumab plus platinum-doublet chemotherapy for neoadjuvant NSCLC treatment 3
- In these combination regimens, nivolumab and chemotherapy remain distinct drug classes working through complementary mechanisms
Bottom line: When patients or providers ask if Opdivo is chemotherapy, the answer is definitively no—it is an immune checkpoint inhibitor that works by unleashing the patient's own immune system rather than directly killing cancer cells like chemotherapy does.